[The novel method for selection of preparations for treatment of arterial hypertension based on spectral analysis of heart rhythm variability].
OBJECTIVE
To study spectral characteristics of heart rhythm in patients with arterial hypertension (AH) to select medication for hypertension and control over the treatment efficacy.


METHODS
35 AH patients were examined with general clinical methods and using spectral analysis of variability of heart rhythm (VHR). Five spectrograms were registered. Each of them contained three peaks: very low, low and high frequencies (VLF, LF and HF, respectively). Normal values of VLF, LF and HF were estimated on the basis of spectral values obtained in healthy subjects. After registration of spectral values all the patients were given at first placebo, than enalapril, one day after its discontinuation--mifedipine. At each stage VHR was recorded. Changes in the spectral indices were compared to changes in clinical symptoms.


RESULTS
VLF proved most important for a rapid choice of adequate antihypertensive therapy.


CONCLUSIONS
Normalization of VLF, LF and HF indicates adequacy of the choice of antihypertensive treatment.
Fleĭshman
A N
AN
Filimonov
S N
SN
Klimina
N V
NV
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D001262:Atenolol / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use; D004656:Enalapril / Q000627:therapeutic use; D005260:Female; D006339:Heart Rate; D006801:Humans; D006973:Hypertension / Q000188:drug therapy* / Q000503:physiopathology; D008297:Male; D008875:Middle Aged; D009543:Nifedipine / Q000627:therapeutic use; D010507:Periodicity
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D001262:Atenolol; D004656:Enalapril; D009543:Nifedipine